Cytophage Technologies (TSXV:CYTO) EV-to-EBITDA : 10.50 (As of May. 28, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cytophage Technologies's enterprise value is C$24.56 Mil. Cytophage Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$2.34 Mil. Therefore, Cytophage Technologies's EV-to-EBITDA for today is 10.50.

The historical rank and industry rank for Cytophage Technologies's EV-to-EBITDA or its related term are showing as below:

TSXV:CYTO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.75 Med: 0 Max: 12.22
Current: 10.5

During the past 3 years, the highest EV-to-EBITDA of Cytophage Technologies was 12.22. The lowest was -19.75. And the median was 0.00.

TSXV:CYTO's EV-to-EBITDA is ranked worse than
51.88% of 451 companies
in the Biotechnology industry
Industry Median: 9.51 vs TSXV:CYTO: 10.50

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), Cytophage Technologies's stock price is C$0.45. Cytophage Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.045. Therefore, Cytophage Technologies's PE Ratio for today is 10.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Cytophage Technologies EV-to-EBITDA Historical Data

The historical data trend for Cytophage Technologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies EV-to-EBITDA Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBITDA

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
EV-to-EBITDA	-	-	-	-	-

Competitive Comparison of Cytophage Technologies's EV-to-EBITDA

For the Biotechnology subindustry, Cytophage Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's EV-to-EBITDA falls into.

Cytophage Technologies EV-to-EBITDA Calculation

Cytophage Technologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	24.561	/	2.34
	=	10.50

Cytophage Technologies's current Enterprise Value is C$24.56 Mil.
Cytophage Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.34 Mil.

Cytophage Technologies (TSXV:CYTO) EV-to-EBITDA Explanation

Cytophage Technologies's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.45	/	0.045
	=	10.00

Cytophage Technologies's share price for today is C$0.45.
Cytophage Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.045.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Cytophage Technologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.